BPMC Blueprint Medicines Corporation

73.2
-0.65  -1%
Previous Close 73.85
Open 73.61
Price To Book 8.52
Market Cap 3569348461
Shares 48,761,591
Volume 147,878
Short Ratio
Av. Daily Volume 493,319

NewsSee all news

  1. 3 Small-Cap Biotech Stocks to Watch Now
  2. Blueprint Medicines Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares of Common Stock
  3. Blueprint Medicines (BPMC) Looks Good: Stock Adds 5.7% in Session
  4. If You Had Bought Blueprint Medicines (NASDAQ:BPMC) Stock Three Years Ago, You Could Pocket A 337% Gain Today
  5. Blueprint Medicines Announces Pricing of Public Offering of Shares of Common Stock

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initial data due 2H 2019.
Avapritinib BLU-285 - PIONEER
Indolent and smoldering systemic mastocytosis (SM)
NDA filing due 2Q 2019.
Avapritinib BLU-285 - NAVIGATOR
PDGFRα driven Gastrointestinal stromal tumors (GIST)
Phase 1 China enrolment to commence mid-2019.
BLU-554
Advanced hepatocellular carcinoma (HCC)
Phase 3 trial planned 1H 2018.
BLU-285
Gastrointestinal stromal tumors (GIST) harboring a PDGFRα D842V
Phase 1 updated data noted ORR 62%. Enrolment to be completed 2Q 2019. NDA filing due 1Q 2020.
BLU-667 - ARROW
RET-altered solid tumors
Phase 2 enrolment to be completed 2H 2019. NDA filing due 1Q 2020.
Avapritinib BLU-285 - PATHFINDER
Advanced Systemic mastocytosis (SM)
Phase 1 updated data due 2Q 2019.
Avapritinib BLU-285 - EXPLORER
Advanced Systemic mastocytosis (SM)
Phase 3 enrolment to be completed 2H 2019.
Avapritinib - Voyager
Gastrointestinal stromal tumors (GIST)
Phase 1 trial initiated 1Q 2019.
BLU-782
Fibrodysplasia ossificans progressiva (FOP)

Latest News

  1. 3 Small-Cap Biotech Stocks to Watch Now
  2. Blueprint Medicines Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares of Common Stock
  3. Blueprint Medicines (BPMC) Looks Good: Stock Adds 5.7% in Session
  4. If You Had Bought Blueprint Medicines (NASDAQ:BPMC) Stock Three Years Ago, You Could Pocket A 337% Gain Today
  5. Blueprint Medicines Announces Pricing of Public Offering of Shares of Common Stock
  6. Blueprint Medicines Expediates Filings for Key Candidates
  7. Blueprint Medicines Announces Proposed Public Offering of Shares of Common Stock
  8. Blueprint Medicines Announces Accelerated Regulatory Submission Plans and Recent Clinical Progress
  9. 5 Cancer-Fighting Stocks to Boost Portfolio Gains
  10. 3 Cancer Treatment Stocks to Buy in March
  11. Blueprint Medicines to Present at 39th Annual Cowen & Co. Health Care Conference
  12. Market Trends Toward New Normal in ITT, Palo Alto Networks, Enterprise Products Partners, Blueprint Medicines, Lincoln Electric, and NewMarket — Emerging Consolidated Expectations, Analyst Ratings
  13. Edited Transcript of BPMC earnings conference call or presentation 26-Feb-19 1:30pm GMT
  14. Blueprint Medicines Corp (BPMC) Q4 2018 Earnings Conference Call Transcript
  15. Blueprint Medicines Reports Fourth Quarter and Full Year 2018 Financial Results
  16. 3 Top Healthcare Stocks to Buy in February
  17. Blueprint Medicines to Report Fourth Quarter and Full Year 2018 Financial Results on Tuesday, February 26, 2019
  18. Earnings Preview: Blueprint Medicines (BPMC) Q4 Earnings Expected to Decline
  19. See what the IHS Markit Score report has to say about Blueprint Medicines Corp.
  20. Blueprint Medicines to Present at Upcoming Investor Conferences in February